ONC:NASDAQ
BeOne Medicines AG
358,07 USD
arrow_downward
-0,20%(-0,70) 1 d.
358,07 USD
0,00% (0,00)
bedtimePo uzavretí
Zavreté: 2. 10., 16:00:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre ONC…
Otvoriť
351,01 USD
Vysoká
358,57 USD
Nízka
349,74 USD
Trh. kap.
43,13 mld.
Priem. obj.
364,38 tis.
Objem
505,17 tis.
Max. za 52 týž.
385,22 USD
Min. za 52 týž.
253,95 USD
Beta
0,61
Akcie v obehu
109,79 mil.
Počet zamestnancov
12 tis.
Otvoriť
351,01 USD
Vysoká
358,57 USD
Nízka
349,74 USD
Trh. kap.
43,13 mld.
Priem. obj.
364,38 tis.
Objem
505,17 tis.
Max. za 52 týž.
385,22 USD
Min. za 52 týž.
253,95 USD
Beta
0,61
Akcie v obehu
109,79 mil.
Počet zamestnancov
12 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Investor's Business Daily
·
pred 3 dňami
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Informácie o subjekte BeOne Medicines AG
Generálny riaditeľJohn Vincent Oyler | John Vincent Oyler
Zamestnanci12 tis.
Dátum založenia28. 10. 2010
Hlavné sídlo-
Odvetvie-